Peptalk← All compounds

Metabolic & Weight Management

Orforglipron

Also known as Foundayo · orfo · LY3502970 · OWL833

Clinically studiedOralFDA-approved (April 2026) as Foundayo (orforglipron) for chronic weight management in adults with obesity or overweight with weight-related comorbidities, used with a reduced-calorie diet and increased physical activity; a separate regulatory filing for type 2 diabetes has been pursued by Eli Lilly based on the Phase 3 ACHIEVE program and was not yet approved at the time of writing. As an FDA-approved branded small-molecule drug, it is not a 503A/503B pharmacy compounding target in the way peptide therapeutics are. For athletes: GLP-1 receptor agonists are not listed on the WADA 2026 Prohibited List but are included in WADA's 2026 Monitoring Program, so competitive athletes should verify current status with their governing body.

Orforglipron is an orally administered, non-peptide small-molecule GLP-1 receptor agonist (a partial agonist) originally discovered by Chugai Pharmaceutical (as OWL833) and developed by Eli Lilly. Like other incretin-based agents, it activates the GLP-1 receptor to influence appetite-regulating brain pathways, enhance glucose-dependent insulin secretion, and slow gastric emptying; unlike peptide GLP-1 drugs, its small-molecule design allows once-daily oral administration without the food, water, or fasting restrictions required by oral semaglutide. The research base is substantial: Phase 3 programs for obesity (ATTAIN) and type 2 diabetes (ACHIEVE) reported statistically significant, dose-dependent reductions in body weight and HbA1c versus placebo, with complete ATTAIN-1 and ACHIEVE-1 results published in the New England Journal of Medicine. In April 2026 the FDA approved it under the brand name Foundayo for chronic weight management, and Eli Lilly has pursued a separate regulatory filing for type 2 diabetes. Reported safety has been consistent with the broader GLP-1 class, with predominantly gastrointestinal adverse events.

Studied / used for

  • Investigated for chronic weight management in adults with obesity or overweight with weight-related comorbidities
  • Studied for glycemic control (HbA1c reduction) in type 2 diabetes (ACHIEVE program)
  • Investigated for cardiometabolic risk markers such as lipids and blood pressure
  • Studied as an oral alternative to injectable and peptide-based GLP-1 receptor agonists

Commonly reported side effects

  • Nausea (commonly reported)
  • Vomiting (commonly reported)
  • Diarrhea (commonly reported)
  • Constipation (commonly reported)
  • Dyspepsia / upset stomach (commonly reported)
Clinically studied. Supported by human clinical trials. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds